Aurinia Pharmaceuticals Inc. (AUPH): Results of Operations and Financial Condition
Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress ROCKVILLE, Maryland and EDMONTON, Alberta – August 6, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced
How this was made
The 30-second read
Why it matters
The most tradable elements are the reiterated 2026 revenue and net product sales guidance ranges, the reported growth in LUPKYNIS net product sales and net income, and the initiation details for the PRESERVE Phase 4 combination study (enrollment size, sites, and primary endpoint).
Market read
This is a company-specific earnings and guidance update with a new Phase 4 study initiation, offering both near-term financial confirmation and a medium-term clinical catalyst.
What to watch
Cash flow strength and the cash balance are supportive, but the filing does not provide updated timelines or interim readouts for PRESERVE, leaving execution and endpoint risk unquantified.
Aurinia reported three-month total revenue of $83.2 million, up 19%, and net income of $37.4 million, up 74%, while reiterating 2026 total revenue guidance of $315 million to $325 million.
Revenue, LUPKYNIS net product sales, net income, diluted earnings per share, and cash flows from operating activities all increased from the comparable 2025 periods. The company also reiterated its 2026 revenue and net product sales guidance and reported $443.1 million of cash, cash equivalents, restricted cash and investments.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $83.2 million | – | 19% |
| Total revenue, six months ended June 30GAAP | $160.9 million | – | 21% |
| Net product salesGAAP | $79.4 million | – | 19% |
| Net product sales, six months ended June 30GAAP | $153.0 million | – | 21% |
| License, collaboration and royalty revenueGAAP | $3.8 million | – | 12% |
| License, collaboration and royalty revenue, six months ended June 30GAAP | $8.0 million | – | 36% |
| Cost of revenueGAAP | $ 6,555 (in thousands) | – | – |
| Cost of revenue, six months ended June 30GAAP | $ 13,060 (in thousands) | – | – |
| Selling, general and administrative expenseGAAP | $ 23,508 (in thousands) | – | – |
| Selling, general and administrative expense, six months ended June 30GAAP | $ 45,537 (in thousands) | – | – |
| Research and development expenseGAAP | $ 13,050 (in thousands) | – | – |
| Research and development expense, six months ended June 30GAAP | $ 20,520 (in thousands) | – | – |
| Restructuring expenseGAAP | — | – | – |
| Restructuring expense, six months ended June 30GAAP | — | – | – |
| Other (income) expense, netGAAP | $ (6,234) (in thousands) | – | – |
| Other (income) expense, net, six months ended June 30GAAP | $ (5,955) (in thousands) | – | – |
| Total operating expensesGAAP | $ 36,879 (in thousands) | – | – |
| Total operating expenses, six months ended June 30GAAP | $ 73,162 (in thousands) | – | – |
| Income from operationsGAAP | $ 46,341 (in thousands) | – | – |
| Income from operations, six months ended June 30GAAP | $ 87,763 (in thousands) | – | – |
| Interest incomeGAAP | $ 3,393 (in thousands) | – | – |
| Interest expenseGAAP | $ (948) (in thousands) | – | – |
| Net income before income taxesGAAP | $ 48,786 (in thousands) | – | – |
| Income tax expenseGAAP | $ 11,372 (in thousands) | – | – |
| Net incomeGAAP | $37.4 million | – | 74% |
| Net income, six months ended June 30GAAP | $71.8 million | – | 60% |
| Basic earnings per shareGAAP | $0.29 | – | – |
| Diluted earnings per shareGAAP | $0.28 | – | 75% |
| Diluted earnings per share, six months ended June 30GAAP | $0.53 | – | 66% |
| Basic shares used in computing earnings per shareGAAP | 130,081 (in thousands) | – | – |
| Diluted shares used in computing earnings per shareGAAP | 133,530 (in thousands) | – | – |
| Cash flows from operating activities, six months ended June 30GAAP | $85.1 million | – | 87% |
| Cash, cash equivalents, restricted cash and investmentsGAAP | $443.1 million | – | – |
| Cash, cash equivalents and restricted cashGAAP | $ 179,832 (in thousands) | – | – |
| Short-term investmentsGAAP | 263,291 (in thousands) | – | – |
| Finance lease liabilities, current portionGAAP | 16,479 (in thousands) | – | – |
| Finance lease liabilities, less current portionGAAP | 43,943 (in thousands) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| LUPKYNIS net product salesNet product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. | $79.4 million | – | 19% |
| License, collaboration and royalty revenueLicense, collaboration and royalty revenue. | $3.8 million | – | 12% |
2026 outlook
- Revenue$315 million to $325 million
- Note2026 net product sales of $305 million to $315 million
- Note2026 total revenue up 11% to 15% compared to 2025
- Note2026 net product sales up 12% to 16% compared to 2025
Capital returns
- Repurchase of 5.0 million of the Company’s common shares for $74.9 million.
- Purchase of common shares under Share Repurchase Plan was $ (74,880) (in thousands) for the six months ended June 30, 2026.
- Proceeds from issuance of common shares for equity awards, net of tax withholding payments, were $32.7 million for the six months ended June 30, 2026.
What drove it
- LUPKYNIS net product sales were $79.4 million for the three months ended June 30, 2026, up 19% from the same period of 2025.
- License, collaboration and royalty revenue was $3.8 million for the three months ended June 30, 2026, up 12% from the same period of 2025.
- Total operating expenses were $ 36,879 (in thousands), compared to $ 49,925 (in thousands) in the same period of 2025.
- Other (income) expense, net was $ (6,234) (in thousands), compared to $ 9,246 (in thousands) in the same period of 2025.
- Aurinia initiated PRESERVE, a Phase 4 multicenter study of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis.
- Aurinia initiated clinical development of aritinercept in four potential indications.
Concerns
- Research and development expense was $ 13,050 (in thousands) for the three months ended June 30, 2026, compared to $ 7,432 (in thousands) in the same period of 2025.
- Income tax expense was $ 11,372 (in thousands) for the three months ended June 30, 2026, compared to $ 643 (in thousands) in the same period of 2025.
- The filing identifies risks associated with LUPKYNIS net product sales and the timing of clinical study results.
What to watch
- Progress of PRESERVE, which has planned enrollment of approximately 150 patients across approximately 50 sites in the US and a primary endpoint of the proportion of patients achieving complete renal response at 6 months.
- LUPKYNIS net product sales relative to the reiterated 2026 guidance of $305 million to $315 million.
- Total revenue relative to the reiterated 2026 guidance of $315 million to $325 million.
- Clinical development of aritinercept in four potential indications.
- Research and development expense following the increase reported for the three months ended June 30, 2026.
Balance sheet and cash flow
- Cash, cash equivalents, restricted cash and investments were $443.1 million as of June 30, 2026, compared to $398.0 million at December 31, 2025.
- Cash flows from operating activities were $52.5 million for the three months ended June 30, 2026, compared to $44.2 million in the same period of 2025.
- Cash flows from operating activities were $85.1 million for the six months ended June 30, 2026, compared to $45.5 million in the same period of 2025.
- Cash flows from investing activities were $ 63,368 (in thousands) for the six months ended June 30, 2026.
- Cash outflows from financing activities were $48.9 million for the six months ended June 30, 2026.
- Finance lease liabilities were $ 16,479 (in thousands) current and $ 43,943 (in thousands) less current portion as of June 30, 2026.
Analysis
Aurinia reported a stronger three-month period, with total revenue of $83.2 million, up 19% from $70.0 million, and LUPKYNIS net product sales of $79.4 million, also up 19% from $66.6 million. License, collaboration and royalty revenue was $3.8 million, up 12% from $3.4 million. For the six months ended June 30, total revenue was $160.9 million, up 21%, while LUPKYNIS net product sales were $153.0 million, up 21%.
Profitability improved materially. Net income was $37.4 million, up 74% from $21.5 million, and diluted earnings per share was $0.28, up 75% from $0.16. Income from operations was $46,341 (in thousands), compared with $20,083 (in thousands). Total operating expenses were $36,879 (in thousands), versus $49,925 (in thousands), with lower cost of revenue and selling, general and administrative expense, as well as other income of $6,234 (in thousands).
Research and development was a notable offset, increasing to $13,050 (in thousands) from $7,432 (in thousands) for the three-month period. Income tax expense also increased to $11,372 (in thousands) from $643 (in thousands). For the six-month period, cash flows from operating activities were $85.1 million, up 87% from $45.5 million, while cash flows from financing activities were an outflow of $48.9 million.
Capital allocation included the repurchase of 5.0 million common shares for $74.9 million during the six months ended June 30, 2026. Cash, cash equivalents, restricted cash and investments totaled $443.1 million at June 30, 2026, compared with $398.0 million at December 31, 2025. Aurinia reiterated 2026 total revenue guidance of $315 million to $325 million and net product sales guidance of $305 million to $315 million.
The development update adds clinical activity alongside the commercial performance. Aurinia initiated the Phase 4 PRESERVE study of LUPKYNIS combinations in lupus nephritis, with planned enrollment of approximately 150 patients across approximately 50 US sites and a six-month complete renal response endpoint. The company also stated that it has initiated clinical development of aritinercept in four potential indications. The key reported items to monitor are LUPKYNIS sales against the reiterated full-year range, R&D expense associated with development activity, and timing of clinical study results.
Not in the filing
stated, not guessed- Prior-quarter comparisons for revenue, expenses, income, earnings per share, cash flow, and balance-sheet metrics were not reported.
- Gross profit and gross margin were not reported.
- Non-GAAP financial measures, including non-GAAP earnings per share, were not reported.
- Free cash flow was not reported.
- A conventional debt balance was not reported.
- Dividend information was not reported.
- Forward guidance for gross margin, operating expenses, tax rate, earnings per share, cash flow, or capital expenditures was not reported.
- Prior-period outlook was not provided; therefore, no comparison of actual results with prior guidance is available.
- Named executive commentary and executive quotes were not provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8-K Item 2.02 with Exhibit 99.1 reporting Aurinia’s financial results for the three and six months ended June 30, 2026 and providing an update on business progress.
Ticker impact
Aurinia reported Q2 and 6M results, reiterated 2026 revenue and LUPKYNIS sales guidance, and initiated the PRESERVE Phase 4 combination study.
Bias modestly positive for the next few sessions, with follow-through dependent on how investors weigh guidance confidence versus clinical execution risk.
The filing provides fresh, specific financial datapoints (revenue, net product sales, EPS, operating cash flow), reiterates 2026 guidance ranges, and discloses a new Phase 4 study initiation with defined enrollment and endpoint.
Market effects
Reinforces demand and commercial durability for an FDA-approved lupus nephritis oral therapy, potentially supporting sentiment toward autoimmune specialty biopharma.
Limited direct regional spillover; primarily impacts US small/mid-cap biotech sentiment.
Low global macro linkage; clinical and commercial updates are company-specific.
Counterpoint
Investors may discount the guidance reiteration if they expect acceleration to slow later in 2026 or if PRESERVE results are needed to sustain longer-term growth.
Key entities
- companyAurinia Pharmaceuticals Inc.
NASDAQ-listed biopharmaceutical company focused on autoimmune diseases; reports LUPKYNIS performance and clinical development updates.
- productLUPKYNIS (voclosporin)
FDA-approved oral therapy for adult patients with active lupus nephritis; drives reported net product sales.
- clinical_studyPRESERVE
Phase 4 multicenter study evaluating LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab; primary endpoint is complete renal response at 6 months.
- pipeline_programAritinercept
Dual BAFF and APRIL inhibitor; Aurinia initiated clinical development in four potential indications.
